Multiple Sclerosis Misdiagnosis Expert Witness: A Litigation Guide for Attorneys
Multiple sclerosis misdiagnosis is a genuine and growing source of medical malpractice litigation, and it runs in both directions. A false-positive MS diagnosis exposes a patient to disease-modifying therapies — some of them carrying serious, even life-threatening adverse risks — for a condition they do not have. A false-negative or delayed diagnosis leaves a patient with true MS untreated while irreversible neurological injury accumulates. Both scenarios produce substantial harm and, when the diagnostic error is traceable to a failure to apply the accepted criteria or order the appropriate confirmatory tests, actionable liability. For attorneys evaluating these cases, understanding the diagnostic standard, the landscape of MS mimics, and the specific risks attached to each class of therapy is the foundation of a credible theory of the case.
The Two Directions of MS Misdiagnosis Litigation
False-positive MS diagnosis is not rare. Published research has documented that a meaningful proportion of patients labeled with MS at community neurology practices do not meet the accepted diagnostic criteria when their records are reviewed by subspecialty neuroimmunologists. When a patient receives a diagnosis of MS and begins therapy — particularly high-efficacy therapies with serious risk profiles — without actually meeting those criteria, the harm flows directly from the diagnostic error. The most catastrophic version of this scenario arises when a patient receives natalizumab or another immunosuppressive DMT and develops a serious adverse event that a correct diagnosis would have prevented.
False-negative and delayed MS diagnosis produces a different harm pattern. Multiple sclerosis is a chronic inflammatory demyelinating disease in which relapse-associated and progressive neurological disability accumulates over time. Evidence supports that early initiation of disease-modifying therapy reduces the frequency of relapses and slows long-term disability accumulation. A patient whose MS goes undiagnosed or is attributed to a non-specific diagnosis while symptoms progress loses that treatment window. The challenge for the plaintiff attorney in these cases is establishing that earlier diagnosis was achievable under the applicable standard of care and that the delay more likely than not worsened the patient's long-term neurological outcome.
The McDonald Criteria: The Diagnostic Standard That Defines Liability
The McDonald criteria — last formally revised in 2017 by an international panel convened by the International MS Federation — are the accepted diagnostic standard for MS worldwide and the framework against which neurologist conduct is measured in litigation. The criteria require demonstration of two elements: dissemination in space (DIS), meaning involvement of at least two anatomically distinct regions of the central nervous system typically affected by MS, and dissemination in time (DIT), meaning that the demyelinating process has occurred on more than one occasion or is ongoing.
Both elements can be established by clinical criteria alone, by MRI criteria, or by a combination. For MRI-based DIS, the criteria require lesions in at least two of four characteristic MS locations: periventricular, cortical or juxtacortical, infratentorial, and spinal cord. For MRI-based DIT, either simultaneous presence of both gadolinium-enhancing and non-enhancing lesions on a single MRI, or a new T2 or gadolinium-enhancing lesion on follow-up imaging, satisfies the requirement.
Cerebrospinal fluid analysis — specifically the presence of oligoclonal bands (OCBs) not found in paired serum — is incorporated into the McDonald criteria as an alternative means of meeting the DIT requirement when imaging evidence is insufficient. The diagnostic significance of OCBs is well-established in the MS literature, and failure to perform a lumbar puncture when the diagnosis cannot be made on imaging alone is itself a potential standard-of-care issue.
The liability framework in false-positive cases is therefore concrete: did the diagnosing neurologist document the presence of both DIS and DIT before attaching the MS label and initiating treatment? Cases where an MS diagnosis was made on the basis of a single lesion, or a single clinical episode without imaging corroboration, or where the imaging findings were present only in atypical locations, provide a documentable gap between the McDonald criteria and the diagnosis actually recorded.
The MS Mimics That Drive False-Positive Diagnoses
A substantial proportion of false-positive MS diagnoses result from failure to consider and exclude conditions that mimic MS on MRI and in clinical presentation. The most consequential mimics, both because they are common and because their treatment differs sharply from MS, are:
Neuromyelitis Optica Spectrum Disorder (NMOSD) — a distinct inflammatory CNS disease caused in the majority of patients by antibodies against aquaporin-4 (AQP4), a water channel protein expressed in astrocytes. NMOSD characteristically produces severe optic neuritis and longitudinally extensive transverse myelitis — clinical presentations that can superficially resemble MS. The critical distinction is that several MS disease-modifying therapies, including natalizumab and fingolimod, have been reported to worsen NMOSD or fail to prevent relapses. A patient with NMOSD who is misdiagnosed as MS and treated with a DMT contraindicated in NMOSD can suffer a catastrophic relapse that would have been prevented by correct diagnosis and appropriate NMOSD-specific immunotherapy.
MOG Antibody-Associated Disease (MOGAD) — a recently characterized inflammatory CNS syndrome in which antibodies against myelin oligodendrocyte glycoprotein produce optic neuritis, myelitis, and cortical encephalitis with a clinical profile that overlaps substantially with both MS and NMOSD. The detection of MOG-IgG in serum is now a standard part of the diagnostic workup for suspected demyelinating disease. Failure to send appropriate antibody panels — including AQP4-IgG and MOG-IgG — before diagnosing MS is increasingly difficult to defend when the clinical presentation has atypical features.
CNS vasculitis, sarcoidosis, and Behçet disease — inflammatory conditions that produce white matter lesions and clinical episodes consistent with CNS demyelination. Distinguishing these from MS requires careful attention to systemic symptoms, atypical MRI morphology, and, in some cases, CSF analysis and targeted autoimmune serologies. Their failure to respond to MS DMTs — and in some cases worsening of symptoms on immunomodulatory therapy — can amplify the harm from a diagnostic error.
Small vessel ischemic disease — MRI white matter hyperintensities from cerebrovascular disease are among the most common sources of false-positive MS diagnoses in older patients. Periventricular and subcortical T2 lesions from small vessel disease lack the juxtacortical and infratentorial predilection of MS lesions and typically do not demonstrate gadolinium enhancement in the acute phase or the characteristic shape and orientation of MS plaques. An expert who reviews the original imaging can frequently identify morphological features clearly inconsistent with the McDonald criteria that a diagnosing clinician overlooked or disregarded.
Standard of Care for DMT Selection and Treatment Escalation
Once an MS diagnosis is appropriately established, the standard of care for disease-modifying therapy selection and escalation generates its own independent category of litigation. Current neuroimmunology practice has moved substantially toward earlier use of higher-efficacy DMTs — a "treat-to-target" framework in which the goal is no evidence of disease activity (NEDA): no clinical relapses, no new MRI lesions, no progression of disability. Persistent MRI activity despite therapy is itself an indicator that treatment escalation is warranted.
Failure to escalate therapy in the face of documented active disease — whether defined by clinical relapse, new gadolinium-enhancing lesions, or progressive T2 lesion burden — is a pattern of substandard care that expert neuroimmunologists regularly identify in litigation. When a patient continues to accumulate lesions and accrue disability while remaining on a lower-efficacy platform therapy without documented consideration of escalation, the question is whether a neurologist exercising reasonable care would have recognized the need for a more potent therapeutic approach.
DMT-Related Adverse Events as Independent Liability Bases
Several MS disease-modifying therapies carry well-characterized serious adverse risks whose monitoring and management create independent standards of care.
Natalizumab (Tysabri) and Progressive Multifocal Leukoencephalopathy (PML) — natalizumab's mechanism of action — blockade of the alpha-4 integrin that lymphocytes use to enter the CNS — creates significant immunosuppression in the brain and increases the risk of PML, a severe and frequently fatal or permanently disabling opportunistic infection caused by reactivation of the JC virus. The risk is stratified by JC antibody seropositivity, antibody index, duration of natalizumab treatment, and prior immunosuppressant exposure. The standard of care requires JC antibody testing before initiation, serial monitoring during treatment, and an informed consent process that specifically addresses PML risk. Cases where a JC antibody-positive patient with a high antibody index continued natalizumab without documented risk-benefit re-evaluation — or where the physician failed to order appropriate surveillance — are frequently litigated.
Alemtuzumab (Lemtrada) and secondary autoimmunity — alemtuzumab produces profound B- and T-cell depletion followed by an immune reconstitution phase during which secondary autoimmune diseases can emerge, including autoimmune thyroid disease, immune thrombocytopenic purpura (ITP), and anti-glomerular basement membrane disease. The standard of care requires rigorous post-infusion monitoring: monthly CBC, serum creatinine, urinalysis, and thyroid function tests for 48 months after the final infusion. Failure to perform or act on this monitoring when it reveals early secondary autoimmunity — particularly when delay in recognizing ITP results in a preventable hemorrhagic event — creates direct liability.
Common Liability Patterns in MS Litigation
### Diagnosing MS Without Meeting McDonald Criteria
The most straightforward liability pattern is a diagnosis of MS documented in the medical record without evidence that DIS and DIT criteria were evaluated or met. Expert analysis begins with the original imaging and clinical records: did the lesion distribution satisfy the spatial criteria? Was there documentation of a second clinical episode or imaging evidence of DIT? Was a lumbar puncture performed and interpreted when imaging evidence was insufficient? When the answer to each of these questions is no, the diagnosis was made without the accepted diagnostic workup, and the harm flows directly from the treatments initiated on that basis.
### Failure to Test for NMOSD and MOGAD Before Starting Therapy
A patient presenting with severe optic neuritis, longitudinally extensive myelitis, or bilateral simultaneous optic neuritis should receive AQP4-IgG and MOG-IgG testing before a DMT is selected. The failure to order these antibody panels before starting a therapy known to be potentially harmful in NMOSD — and then treating a relapse attributable to NMOSD-specific pathophysiology as an MS relapse — represents a recognizable deviation from the diagnostic standard.
### Inadequate PML Monitoring During Natalizumab Therapy
Annual or biannual brain MRI with FLAIR and diffusion-weighted sequences is a recognized component of PML surveillance in JC-positive patients on natalizumab. When PML is detected late because surveillance MRI was not ordered at appropriate intervals, the extent of the resulting white matter injury and disability is directly proportional to the duration of undetected viral replication. An expert can reconstruct the MRI timeline, identify when prodromal PML lesions would have been detectable on imaging, and establish the preventable component of the injury.
Daubert and Admissibility Considerations
MS misdiagnosis cases require expert witnesses who are not merely board-certified neurologists but fellowship-trained neuroimmunologists with active experience diagnosing and treating MS, NMOSD, and MOGAD under current criteria. Courts have increasingly recognized that the clinical questions at issue in these cases — application of the McDonald criteria, antibody testing interpretation, DMT risk stratification, and PML surveillance standards — are subspecialty questions that require subspecialty credentials.
An expert opining that a patient's MRI did not meet McDonald criteria for DIS must be qualified to interpret neuroradiological findings relevant to MS. While a neuroradiologist provides independent imaging interpretation, the neuroimmunologist's ability to apply the McDonald criteria to those findings is itself a specialized skill that goes beyond general neurology training.
Causation in DMT adverse-event cases requires the expert to connect the monitoring failure or prescribing decision to the specific adverse outcome using the published pharmacovigilance data and monitoring guidelines — not personal clinical opinion alone. A causation opinion on PML that is grounded in the JC antibody risk stratification data and the published MRI surveillance literature will withstand Daubert scrutiny; one that relies on personal clinical impression without that methodological anchoring will not.
How ApexMedLaw Supports Multiple Sclerosis Litigation
Multiple sclerosis misdiagnosis and DMT-related adverse event cases demand experts who actively practice neuroimmunology — who apply the McDonald criteria daily, who order and interpret AQP4 and MOG antibody panels, who stratify natalizumab-associated PML risk, and who manage secondary autoimmunity after alemtuzumab. Our neuroimmunology division features fellowship-trained neuroimmunologists with active experience in relapsing and progressive MS, NMOSD, MOGAD, and other immune-mediated neurological conditions.
We provide:
- Case screening and review of imaging, antibody panels, CSF results, and the diagnostic record for McDonald criteria compliance
- Expert analysis of DMT selection decisions, escalation timing, and adherence to monitoring standards for natalizumab, alemtuzumab, and other high-efficacy therapies
- Causation opinions connecting diagnostic error or monitoring failure to patient harm
- Analysis of NMOSD and MOGAD cases where a misdiagnosis of MS led to the use of contraindicated therapy
- Evaluation of false-negative MS cases where delayed diagnosis allowed preventable disability accumulation
- Deposition and trial-ready testimony from board-certified, fellowship-trained neuroimmunologists in active clinical practice
Whether the case turns on a McDonald criteria gap in the original diagnostic workup, a failure to order AQP4 or MOG antibody testing before treating a demyelinating syndrome as MS, a PML event attributable to inadequate monitoring, or a secondary autoimmune complication from alemtuzumab that monitoring protocols would have caught early, our experts evaluate the clinical record against current neuroimmunology standards and deliver opinions that withstand cross-examination and Daubert scrutiny.
Contact ApexMedLaw to discuss your multiple sclerosis misdiagnosis case.
This article is for informational purposes and does not constitute legal advice. Medical-legal standards vary by jurisdiction.